Day: May 16, 2022

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the first quarter ended March 31, 2022. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are extremely proud of the progress we have made this quarter to transition NightHawk into a fully-integrated biopharmaceutical company. On the business front, this month we announced the name change to NightHawk Biosciences to better reflect our evolution towards a fully integrated ecosystem that enables more rapid delivery of medical innovations with increased quality and efficiency. The NightHawk ecosystem includes an expanded development pipeline and...

Company Achieves 679% Year-Over-Year Revenue Growth as Part of Successful Acquisition Strategy Gross Profit Margin Increases to 34.1% Versus 3.7% for the Same Period Last Year MIAMI, May 16, 2022 (GLOBE NEWSWIRE) — Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leading developer, marketer, and manufacturer of nutritional and related products, today provided a business update and reported financial results for the first quarter ended March 31, 2022. “I am pleased to report we achieved significant growth in revenue as a result of both organic growth and the successful implementation of our acquisition strategy, to $4.5 million this quarter,” stated Darren Minton, Chief Executive Officer of Smart for Life. “By acquiring three companies, including Doctors Scientific Organica (DSO), Nexus Offers (Nexus)...

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the quarter ending March 31, 2022. Product and Pipeline Updates and Other Corporate Developments ZIMHIAccording to the Centers for Disease Control and Prevention (CDC), drug overdoses resulted in over 108,000 deaths in the U.S. over the most recent 12 months of data. Two thirds of these involved fentanyl.Our U.S. commercial partner, US WorldMeds, commercially launched our high dose naloxone product, ZIMHI, at the end of March.We are encouraged by the early acceptance of ZIMHI...

EUGENE, Ore., May 16, 2022 (GLOBE NEWSWIRE) — Arcimoto, Inc.® (NASDAQ: FUV), makers of rightsized, outrageously fun, ultra-efficient electric vehicles for moving people and stuff, today provided a corporate update and announced financial results for the first quarter ended March 31, 2022. Arcimoto will host a stakeholder and analyst webinar today to discuss the company’s results. The webinar will include an investor Q&A powered by Say. To view the webcast, use the links below: First Quarter 2022 Stakeholder WebcastDate: Monday, May 16, 2022Time: 5:00 p.m. ET (2:00 p.m. PDT)Webcast: https://us06web.zoom.us/webinar/register/WN_b7xY14wtTpWJNDkAI538NA First Quarter 2022 and Recent Company HighlightsIn Q1, sold 24 new customer vehicles while shifting manufacturing operations from the AMP to the RAMP. Launched operations at RAMP,...

Company Revenue Increases 31% Sequentially to $13.1 Million in First Quarter of 2022 Second Consecutive Quarter of Margin Improvement Despite Industry-Wide Supply Challenges Company Triples MP Performance Energy Sales in First Quarter of 2022 from Fourth Quarter of 2021 to Over $1.1 Million; Delivers Energy Margins of 35% in First Quarter of 2022 LAS VEGAS, May 16, 2022 (GLOBE NEWSWIRE) — MusclePharm Corporation (“MusclePharm” or the “Company”) (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, today reported financial results for the first quarter ended March 31, 2022. Mr. Ryan Drexler, the Chairman of the Board of Directors and Chief Executive Officer, stated, “We delivered sequential revenue improvement in the first quarter of 2022 with revenue of $13.1 million, up from...

PHOENIX, May 16, 2022 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB:MFON), maker of the award-winning Recurrency platform that increases customer engagement through mobile messaging and personalized digital offers, and drives digital transformation for brands, today announced financial results for the first quarter (“Q1”) ending March 31, 2022. First Quarter 2022 Financial HighlightsRevenues of $2.0 million compared to $2.5 million in Q1 2021. The year-over-year decrease in revenue was primarily due to the restructuring of a large customer contract due to COVID related changes in their business. Gross margin of 42.1% compared to 57.6% in Q1 2021. The decrease in gross margin was primarily due to the restructuring of the aforementioned large customer contract. Net loss was $1.9 million compared to $1.7 million in Q1 2021. Cash...

– $130 Million in Non-Dilutive Capital Strengthened Financial Position – – Presentations at Upcoming ASGCT Annual Meeting Include First-Time Details of Mechanism of Action of Nuclease-Free Gene Editing Candidate HMI-103 for PKU; Symposium to Feature Lead Principal Investigator for the pheEDIT Trial – – Additional Presentations on GTx-mAb Platform and Characterization of Proprietary AAVHSC Capsid with Low Liver Tropism – – Submitted Response to FDA with Information Requested for pheNIX Gene Therapy Trial Clinical Hold – BEDFORD, Mass., May 16, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments. “During the first quarter of 2022,...